New research suggests glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia and Alzheimer's disease in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
Patients with CKD and T2DM face an increased risk of cognitive decline. While GLP-1RAs are used for blood sugar control and offer cardiovascular and renal benefits, their neuroprotective potential is an emerging area of study.
A retrospective cohort study analyzed data from over 67 healthcare organizations in the USA. Researchers compared adults with CKD stage 3 or later and T2DM who were newly prescribed either a GLP-1RA or a dipeptidyl peptidase-4 inhibitor (DPP4i).
The study found that GLP-1RA therapy was associated with a 20% lower risk of overall dementia compared to DPP4i use. The risk of Alzheimer's disease specifically was reduced by 24%.
These findings suggest that GLP-1RAs may offer neuroprotective benefits beyond their known effects on blood sugar control in this high-risk population. Further research is needed to confirm these associations.